165 related articles for article (PubMed ID: 24141239)
1. Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients.
Esterson YB; Zhang K; Koppaka S; Kehlenbrink S; Kishore P; Raghavan P; Maginley SR; Carey M; Hawkins M
J Investig Med; 2013 Dec; 61(8):1152-60. PubMed ID: 24141239
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study.
Tripathy D; Daniele G; Fiorentino TV; Perez-Cadena Z; Chavez-Velasquez A; Kamath S; Fanti P; Jenkinson C; Andreozzi F; Federici M; Gastaldelli A; Defronzo RA; Folli F
Diabetologia; 2013 Oct; 56(10):2153-63. PubMed ID: 23811853
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory effects of troglitazone in nondiabetic obese subjects independent of changes in insulin sensitivity.
van Tits LJ; Arioglu-Oral E; Sweep CG; Smits P; Stalenhoef AF; Tack CJ
Neth J Med; 2005; 63(7):250-5. PubMed ID: 16093575
[TBL] [Abstract][Full Text] [Related]
4. Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein β up-regulation.
Powell LA; Crowe P; Kankara C; McPeake J; McCance DR; Young IS; Trimble ER; McGinty A
Clin Sci (Lond); 2012 Aug; 123(3):135-46. PubMed ID: 22309242
[TBL] [Abstract][Full Text] [Related]
5. High circulating levels of RBP4 and mRNA levels of aP2, PGC-1alpha and UCP-2 predict improvement in insulin sensitivity following pioglitazone treatment of drug-naïve type 2 diabetic subjects.
Hammarstedt A; Pihlajamäki J; Graham TE; Kainulainen S; Kahn BB; Laakso M; Smith U
J Intern Med; 2008 Apr; 263(4):440-9. PubMed ID: 18324929
[TBL] [Abstract][Full Text] [Related]
6. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
Maffioli P; Fogari E; D'Angelo A; Perrone T; Derosa G
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1113-22. PubMed ID: 23524525
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
Derosa G; Mereu R; Salvadeo SA; D'Angelo A; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
Intern Med; 2009; 48(5):265-71. PubMed ID: 19252346
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Cusi K; Orsak B; Bril F; Lomonaco R; Hecht J; Ortiz-Lopez C; Tio F; Hardies J; Darland C; Musi N; Webb A; Portillo-Sanchez P
Ann Intern Med; 2016 Sep; 165(5):305-15. PubMed ID: 27322798
[TBL] [Abstract][Full Text] [Related]
9. Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes.
Kovacova Z; Tharp WG; Liu D; Wei W; Xie H; Collins S; Pratley RE
Obesity (Silver Spring); 2016 Apr; 24(4):820-8. PubMed ID: 26887289
[TBL] [Abstract][Full Text] [Related]
10. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
Gastaldelli A; Harrison SA; Belfort-Aguilar R; Hardies LJ; Balas B; Schenker S; Cusi K
Hepatology; 2009 Oct; 50(4):1087-93. PubMed ID: 19670459
[TBL] [Abstract][Full Text] [Related]
11. Effects of pioglitazone on insulin sensitivity and serum lipids in obese cats.
Clark M; Thomaseth K; Dirikolu L; Ferguson DC; Hoenig M
J Vet Intern Med; 2014; 28(1):166-74. PubMed ID: 24592408
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone ameliorates endothelial dysfunction in those with impaired glucose regulation among the first-degree relatives of type 2 diabetes mellitus patients.
Yu X; Chen P; Wang H; Zhu T
Med Princ Pract; 2013; 22(2):156-60. PubMed ID: 22964975
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes.
Tonelli J; Li W; Kishore P; Pajvani UB; Kwon E; Weaver C; Scherer PE; Hawkins M
Diabetes; 2004 Jun; 53(6):1621-9. PubMed ID: 15161771
[TBL] [Abstract][Full Text] [Related]
14. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
[TBL] [Abstract][Full Text] [Related]
15. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
16. Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance.
Serlie MJ; Allick G; Groener JE; Ackermans MT; Heijligenberg R; Voermans BC; Aerts JM; Meijer AJ; Sauerwein HP
J Clin Endocrinol Metab; 2007 Jan; 92(1):166-71. PubMed ID: 17062758
[TBL] [Abstract][Full Text] [Related]
17. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial.
Smith SR; De Jonge L; Volaufova J; Li Y; Xie H; Bray GA
Metabolism; 2005 Jan; 54(1):24-32. PubMed ID: 15562376
[TBL] [Abstract][Full Text] [Related]
18. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
Yu JG; Javorschi S; Hevener AL; Kruszynska YT; Norman RA; Sinha M; Olefsky JM
Diabetes; 2002 Oct; 51(10):2968-74. PubMed ID: 12351435
[TBL] [Abstract][Full Text] [Related]
19. Phenotyping of adipose, liver, and skeletal muscle insulin resistance and response to pioglitazone in spontaneously obese rhesus monkeys.
Shang J; Previs SF; Conarello S; Chng K; Zhu Y; Souza SC; Staup M; Chen Y; Xie D; Zycband E; Schlessinger K; Johnson VP; Arreaza G; Liu F; Levitan D; Wang L; van Heek M; Erion M; Wang Y; Kelley DE
Am J Physiol Endocrinol Metab; 2017 Apr; 312(4):E235-E243. PubMed ID: 28143858
[TBL] [Abstract][Full Text] [Related]
20. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]